Neurosterix
neurosterix.com
Actively hiring
Financial Services
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
1
Xontogeny
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Xontogeny Similar startupsby what they do, their industry and backers
Constructive Bio designs and manufactures new-to-nature chemistries for next-generation therapies and materials.
Empowering living medicines.. Encellin is focused on advancing next generation therapies, starting with endocrine disorders.
Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1. Terrestrial.
AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet…
G1 Therapeutics, Inc. is a commercial stage oncology company focused on the development and commercialization of next generation therapies…
Next Generation Financial Technology Platform for Creators and Brands.
News
Addex spin-out company Neurosterix on track to complete phase 1 study of NTX-253 for schizophrenia in Q2 2026
Addex spin-out company Neurosterix on track to complete phase 1 study of NTX-253 for schizophrenia in Q2 2026
Read more
Report
Report
Neurosterix launches with $63 million to advance allosteric modulator therapeutics
A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and development of allosteric modulator therapeutics to address underserved neurological disorders.According to a release from Neurosterix, the fund
Read more
Report
Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders
The post Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders appeared first on Neurosterix.
Read more
Report
Neurosterix emerges with $63m for neuroscience pipeline
New biotech Neurosterix has been formed to develop allosteric modulators originated at Addex, including a candidate for schizophrenia.
Read more
Report
Pro access
Upgrade to see all 7 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.